ArticleFrontiers in psychiatry2020
New Users of Antipsychotics Among Children and Adolescents in 2008-2017: A Nationwide Register Study.
Article in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Cardiometabolic adverse effects of long-term antipsychotic treatment in children and adolescents with non-psychotic disorders: a systematic review of available evidence.European child & adolescent psychiatry · 2025Pooled it
- The role of metformin in treatment of weight gain associated with atypical antipsychotic treatment in children and adolescents: A systematic review and meta-analysis of randomized controlled trials.Frontiers in psychiatry · 2022Pooled it
- Trial
- Trends in antipsychotic drug utilisation and indication in the paediatric population: a nationwide cohort study in Sweden.BMJ mental health · 2026Article
- Drug utilisation of antipsychotics and lithium in Sweden 2008-2021 - a nationwide study of children aged 5-17 years.European child & adolescent psychiatry · 2026Article
- Prescriber-recorded indications for antipsychotic use in children and adolescents in Spain, 2015-2023: a population-based, real-world study.European child & adolescent psychiatry · 2026Article
- Trends in Atypical Antipsychotic Use Among Children and Adolescents With Depressive Disorders in Korea.Journal of Korean medical science · 2026Article
- Psychotropic dispensing in Greek adolescents and young adults: national trends and regional variation.Frontiers in drug safety and regulation · 2026Article
- Low to moderate-dose off-label use of second-generation antipsychotics seems to be safe in the light of cardiac adverse effects in child psychiatric patients.European journal of pediatrics · 2025Article
- Long-Acting Injectable Antipsychotic Use in Children and Adolescents in Comparison to Adults.Journal of clinical medicine · 2025Article
- Paliperidone-Induced Massive Asymptomatic Creatine Kinase Elevation in Youth: From a Case Report to Literature Review.Pediatric reports · 2025Review
- Comparison of antipsychotic drug use in children and adolescents in the Netherlands before and during the COVID-19 pandemic.European child & adolescent psychiatry · 2024Article
- Trends and off-label utilization of antipsychotics in children and adolescents from 2016 to 2021 in China: a real-world study.Child and adolescent psychiatry and mental health · 2024Article
- Antipsychotic prescribing patterns in children and adolescents attending Australian general practice in 2011 and 2017.JCPP advances · 2024Article
- Editorial: Psychotropic overprescribing to youth: scope of the problem, causes, and possible solutions.Frontiers in psychiatry · 2024Article
- Comparison of antipsychotic drug use among Dutch Youth before and after implementation of the Youth Act (2010-2019).European child & adolescent psychiatry · 2023Article
- Trends in antipsychotic use among children and adolescents in Germany: a study using 2011-2020 nationwide outpatient claims data.Frontiers in psychiatry · 2023Article
- Association of mental health and behavioral disorders with health care and service utilization in children before and after diagnosis.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRecently, prescribing antipsychotics for children and adolescents has been increasing in many countries. These drugs are often prescribed off-label, although antipsychotics have been associated with adverse effects. We determined the recent incidence of antipsychotic use among children and adolescents in Finland.
methodsFinnish National Prescription Register including all Finnish inhabitants receiving reimbursement for pharmaceuticals was searched for subjects of 1 to 17 years of age who had started an antipsychotic drug between January 1, 2008, and December 31, 2017 (n = 26,353). Between 2008 and 2017, the range of number of Finnish children and adolescents aged 1 to 17 years was 1.01 to 1.03 million/year. The incidence was calculated by dividing the number of new users by all age- and sex-matched Finnish inhabitants in the year.
resultsBetween 2008 and 2017, the incidence of antipsychotic use among children and adolescents increased from 2.1 to 3.8 per 1000 individuals, respectively. In children aged 7 to 12 years, the incidence of antipsychotic use 1.4-folded (from 1.9 (95% CI: 1.8-2.0) to 2.7 (95% CI: 2.5-2.9) per 1000) with a cumulative increase of 0.2% per year (χ
conclusionsThe incidence of antipsychotic use increased between 2008 and 2017, especially in adolescent girls. The use of quetiapine increased, although it has few official indications in children and adolescents. Future studies should investigate the reasons for increasing use of antipsychotics, especially quetiapine, in children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.